Drug Approval | March 17, 2022
USFDA approves Rinvoq for ulcerative colitis
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
The investment will accelerate the overall Sarclisa development program
Machine learning approach to systems biology combined with ligand discovery platform
SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
